ClinicalTrials.gg

Program

bizalimogene ralaplasmid

Also written as “VGX-3100” and “VGX 3100”.

Its studies are mostly in Uterine Cervical Dysplasia · Squamous Intraepithelial Lesions · Anus Neoplasms · Uterine Cervical Neoplasms · Papillomavirus Infections, led by Inovio Pharmaceuticals.

Furthest: phase 3, since Jun 9, 20177 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Inovio Pharmaceuticals70 open or runningphase 3since Jun 9, 2017May 22, 2008none ahead
  • Named in fosun pharma’s own pipeline as VGX-3100, phase 3, as of Sep 21, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 22, 2008First study: phase 1 study in Papillomavirus InfectionsFirst studyNCT00685412 · 18 enrolled · United States, Puerto Rico
  2. Aug 5, 2010Phase 1 study in Uterine Cervical NeoplasmsNCT01188850 · 14 enrolled · United States, Puerto Rico
  3. Feb 16, 2011Phase 2 study in Uterine Cervical DysplasiaNCT01304524 · 167 enrolled · United States, Australia, Canada and more
  4. Jun 6, 2017Phase 2 study in Vulvar High Grade Squamous Intraepithelial Lesion (HSIL)NCT03180684 · 33 enrolled · United States
  5. Jun 9, 2017Phase 3 study in Uterine Cervical DysplasiaNCT03185013 · 201 enrolled · United States, Argentina, Belgium and more
  6. Apr 9, 2018Phase 2 study in Anus NeoplasmsNCT03499795 · 23 enrolled · United States, Canada
  7. Oct 25, 2018Phase 3 study in Uterine Cervical DysplasiaNCT03721978 · 203 enrolled · United States, Argentina, Brazil and more

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03721978Uterine Cervical Dysplasia · United States, Argentina, Brazil and more3CompletedAug 23, 2022203
NCT03499795Anus Neoplasms · United States, Canada2CompletedJun 16, 202023
NCT03185013Uterine Cervical Dysplasia · United States, Argentina, Belgium and more3CompletedJul 8, 2020201
NCT03180684Vulvar High Grade Squamous Intraepithelial Lesion (HSIL) · United States2CompletedJul 23, 202033
NCT01304524Uterine Cervical Dysplasia · United States, Australia, Canada and more2CompletedMay 2014167
NCT01188850Uterine Cervical Neoplasms · United States, Puerto Rico1CompletedOct 201114
NCT00685412Papillomavirus Infections · United States, Puerto Rico1CompletedJan 201118

How it is read

Names in the registry

  • “VGX-3100”, 6 entries
  • “VGX 3100”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.